Stock MBIO MUSTANG BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
0.2601 USD +4.88% Intraday chart for Mustang Bio, Inc. -25.71% -80.73%
Apr. 30 Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants MT
Apr. 15 North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions DJ

Evolution of the average Target Price on Mustang Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0f65cda91e81ccc502e90d03b98541a.3sYaauveN77zXWb7Dur9V58JCOlOrcphT7M2OPH7NfE.jPNuA6GxVMyWFgmYYtKzGspEQJwFy7sOB9FfYsOMXJuUqFA9p4t-16MyMw~f2dfcdc372d24171af9e3db99b007507

Analyst Recommendations on Mustang Bio, Inc.

Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants MT
BTIG Adjusts Price Target on Mustang Bio to $16 From $20, Maintains Buy Rating MT
BTIG Raises Price Target on Mustang Bio to $20 From $4, Maintains Buy Rating MT
B. Riley Adjusts Mustang Bio's Price Target to $10 From $4 After Model Updates, Reverse Stock Split; Keeps Buy Rating MT
BTIG Adjusts Mustang Bio's Price Target to $4 From $8, Keeps Buy Rating MT
Oppenheimer Adjusts Mustang Bio Price Target to $4 From $8, Maintains Outperform Rating MT
B. Riley Securities Trims Mustang Bio's Price Target to $4 from $5, Keeps Buy Rating MT
B. Riley Trims Mustang Bio's Price Target to $5 from $6 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions, Keeps Buy Rating MT
B. Riley Lowers Mustang Bio's Price Target to $6 from $13 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
Mustang Bio Says Data From Cancer Treatment MB-106 Trial Shows Overall Response Rate of 95% MT
Oppenheimer Adjusts Mustang Bio PT to $8 From $11, Maintains Outperform Rating MT
MUSTANG BIO : BTIG Initiates Mustang Bio at Buy Rating With $11 Price Target MT
MUSTANG BIO : Oppenheimer Adjusts Mustang Bio PT to $11 From $13, Maintains Outperform Rating MT
MUSTANG BIO : B. Riley Reinstates Mustang Bio With Buy Rating, $13 Price Target MT
MUSTANG BIO : B. Riley Adjusts Mustang Bio's Price Target to $13 From $9, Keeps Buy Rating MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2601 USD
Average target price
17.5 USD
Spread / Average Target
+6,628.18%
High Price Target
25 USD
Spread / Highest target
+9,511.69%
Low Price Target
10 USD
Spread / Lowest Target
+3,744.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Mustang Bio, Inc.

BTIG
B. Riley
Oppenheimer

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MBIO Stock
  4. Consensus Mustang Bio, Inc.